These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36662612)

  • 21. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.
    Maccioni L; Leclercq IA; Schnabl B; Stärkel P
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of Gut Microbiota by Magnesium Isoglycyrrhizinate Mediates Enhancement of Intestinal Barrier Function and Amelioration of Methotrexate-Induced Liver Injury.
    Xia Y; Shi H; Qian C; Han H; Lu K; Tao R; Gu R; Zhao Y; Wei Z; Lu Y
    Front Immunol; 2022; 13():874878. PubMed ID: 35634319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outside the liver box: The gut microbiota as pivotal modulator of liver diseases.
    Wahlström A
    Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):912-919. PubMed ID: 31007175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intestinal microbiota in liver disease.
    Haque TR; Barritt AS
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):133-42. PubMed ID: 27048904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension promotes microbial translocation and dysbiotic shifts in the fecal microbiome of nonhuman primates.
    Vemuri R; Ruggiero A; Whitfield JM; Dugan GO; Cline JM; Block MR; Guo H; Kavanagh K
    Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H474-H485. PubMed ID: 35148233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microbiota, cirrhosis, and the emerging oral-gut-liver axis.
    Acharya C; Sahingur SE; Bajaj JS
    JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The gut microbiota-bile acid axis: A potential therapeutic target for liver fibrosis.
    Zhang YL; Li ZJ; Gou HZ; Song XJ; Zhang L
    Front Cell Infect Microbiol; 2022; 12():945368. PubMed ID: 36189347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut microbiome and liver diseases.
    Tilg H; Cani PD; Mayer EA
    Gut; 2016 Dec; 65(12):2035-2044. PubMed ID: 27802157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis.
    Fan Y; Li Y; Chu Y; Liu J; Cui L; Zhang D
    Front Immunol; 2021; 12():608498. PubMed ID: 33708204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microbiome-liver crosstalk: A multihit therapeutic target for liver disease.
    Kirundi J; Moghadamrad S; Urbaniak C
    World J Gastroenterol; 2023 Mar; 29(11):1651-1668. PubMed ID: 37077519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial proteins: intestinal guards to protect against liver disease.
    Hendrikx T; Schnabl B
    J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
    Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
    Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
    Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
    Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of gut microbiota in liver disease.
    Albhaisi SAM; Bajaj JS; Sanyal AJ
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G84-G98. PubMed ID: 31657225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis.
    Chen YX; Lai LN; Zhang HY; Bi YH; Meng L; Li XJ; Tian XX; Wang LM; Fan YM; Zhao ZF; Han DW; Ji C
    World J Gastroenterol; 2016 Mar; 22(10):2949-59. PubMed ID: 26973391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut-liver axis: Pathophysiological concepts and clinical implications.
    Tilg H; Adolph TE; Trauner M
    Cell Metab; 2022 Nov; 34(11):1700-1718. PubMed ID: 36208625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
    Mungamuri SK; Vijayasarathy K
    Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.